Fairfield, Bush & Co. Novartis Ag Transaction History

Fairfield, Bush & Co.

$158 Billion
Q1 2025

A detailed history of Fairfield, Bush & Co. transactions in Novartis Ag stock. As of the latest transaction made, Fairfield, Bush & Co. holds 25,052 shares of NVS stock, worth $2.8 Million. This represents 1.77% of its overall portfolio holdings.

Number of Shares

25,052

Previous 25,516 1.82%

Holding current value

$2.8 Million

Previous $2.48 Billion 12.48%

% of portfolio

1.77%

Previous 1.46%

31 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 13, 2025	SELL	$97.14 - $115.57 $45,072 - $53,624	-464 Reduced 1.82%	25,052 $2.79 Billion
Q4 2024 Feb 13, 2025	BUY	$96.78 - $117.18 $54,874 - $66,441	567 Added 2.27%	25,516 $2.48 Billion
Q3 2024 Nov 12, 2024	SELL	$106.13 - $120.89 $389,284 - $443,424	-3,668 Reduced 12.82%	24,949 $2.87 Billion
Q2 2024 Aug 15, 2024	SELL	$92.57 - $107.37 $17,773 - $20,615	-192 Reduced 0.67%	28,617 $3.05 Billion
Q1 2024 May 15, 2024	SELL	$95.27 - $108.47 $57,447 - $65,407	-603 Reduced 2.05%	28,809 $2.79 Billion
Q4 2023 Feb 13, 2024	SELL	$92.27 - $101.54 $362,067 - $398,442	-3,924 Reduced 11.77%	29,412 $2.97 Billion
Q3 2023 Nov 15, 2023	SELL	$94.73 - $105.13 $710,475 - $788,475	-7,500 Reduced 18.37%	33,336 $3.4 Billion
Q2 2023 Aug 15, 2023	SELL	$92.52 - $104.91 $34,695 - $39,341	-375 Reduced 0.91%	40,836 $4.12 Billion
Q1 2023 May 15, 2023	BUY	$80.03 - $92.81 $597,103 - $692,455	7,461 Added 22.11%	41,211 $3.79 Billion
Q4 2022 Feb 14, 2023	SELL	$75.55 - $92.52 $22,060 - $27,015	-292 Reduced 0.86%	33,750 $3.06 Billion
Q3 2022 Nov 07, 2022	SELL	$74.61 - $87.26 $231,514 - $270,767	-3,103 Reduced 8.35%	34,042 $2.59 Million
Q2 2022 Aug 09, 2022	SELL	$80.52 - $93.75 $360,568 - $419,812	-4,478 Reduced 10.76%	37,145 $3.14 Million
Q1 2022 May 06, 2022	BUY	$80.11 - $90.62 $4,646 - $5,255	58 Added 0.14%	41,623 $3.65 Million
Q4 2021 Feb 09, 2022	SELL	$79.7 - $88.13 $918,542 - $1.02 Million	-11,525 Reduced 21.71%	41,565 $3.64 Million
Q3 2021 Nov 08, 2021	SELL	$81.78 - $95.14 $719,991 - $837,612	-8,804 Reduced 14.22%	53,090 $4.34 Million
Q2 2021 Aug 02, 2021	SELL	$85.24 - $94.15 $265,011 - $292,712	-3,109 Reduced 4.78%	61,894 $5.65 Million
Q1 2021 May 14, 2021	SELL	$83.5 - $98.47 $50,935 - $60,066	-610 Reduced 0.93%	65,003 $5.56 Million
Q3 2020 Nov 18, 2020	SELL	$82.14 - $91.0 $3,285 - $3,640	-40 Reduced 0.06%	65,613 $5.71 Million
Q2 2020 Aug 13, 2020	SELL	$80.93 - $91.1 $6,393 - $7,196	-79 Reduced 0.12%	65,653 $5.73 Million
Q1 2020 May 13, 2020	SELL	$70.67 - $99.01 $119,290 - $167,128	-1,688 Reduced 2.5%	65,732 $5.42 Million
Q4 2019 Feb 12, 2020	SELL	$84.35 - $95.37 $58,960 - $66,663	-699 Reduced 1.03%	67,420 $6.38 Million
Q3 2019 Nov 13, 2019	SELL	$85.54 - $94.26 $253,369 - $279,198	-2,962 Reduced 4.17%	68,119 $5.92 Million
Q2 2019 Aug 13, 2019	SELL	$75.4 - $92.8 $533,228 - $656,281	-7,072 Reduced 9.05%	71,081 $6.49 Million
Q1 2019 May 15, 2019	SELL	$75.32 - $86.15 $74,416 - $85,116	-988 Reduced 1.25%	78,153 $7.51 Million
Q4 2018 Feb 11, 2019	SELL	$73.66 - $82.02 $36,461 - $40,599	-495 Reduced 0.62%	79,141 $6.79 Million
Q3 2018 Nov 13, 2018	SELL	$66.94 - $77.43 $559,149 - $646,772	-8,353 Reduced 9.49%	79,636 $6.86 Million
Q2 2018 Aug 16, 2018	SELL	$64.91 - $73.36 $291,900 - $329,899	-4,497 Reduced 4.86%	87,989 $6.65 Million
Q1 2018 May 09, 2018	SELL	$70.39 - $84.15 $507,300 - $606,469	-7,207 Reduced 7.23%	92,486 $7.48 Million
Q4 2017 Feb 22, 2018	BUY	$72.33 - $77.64 $355,574 - $381,678	4,916 Added 5.19%	99,693 $8.37 Million
Q3 2017 Nov 14, 2017	SELL	$74.14 - $77.27 $2,594 - $2,704	-35 Reduced 0.04%	94,777 $8.14 Million
Q2 2017 Aug 15, 2017	BUY	N/A	94,812	94,812 $7.91 Million

Others Institutions Holding NVS

# of Institutions

1,524

Shares Held

142M

Call Options Held

1.63M

Put Options Held

1.82M

View Full List

About NOVARTIS AG

Ticker NVS
Exchange OTC
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 2,151,000,064
Market Cap $241B
Description
Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology, dermatol...

More about NVS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Fairfield, Bush & Co., based on Form 13F filings with the SEC.

News

Stay updated on Fairfield, Bush & Co. with notifications on news.

Account

Fairfield, Bush & Co. Novartis Ag Transaction History